Plasma ProfilingNational facility
The Plasma Profiling Facility offers a high level of capabilities and a long-standing expertise in affinity proteomic analysis of human body fluids. Our services aim to support researchers and clinicians in the fields of translational and personalized medicine in their efforts for multiplexed protein quantification.
The facility hosts a unique combination of several advanced technologies and access to more than 50,000 antibodies from the Human Protein Atlas. With our infrastructure and proficiency, we support the progress in translational research from biomarker discovery to validation in a large number of samples and a variety of human conditions. Our expertise and level of support also includes other aspects of the protein profiling pipeline such as experimental study design, selection of antibody, antibody validation, data processing and statistical analysis. We also advise and develop alternative assays tailored for the specific needs of the user's projects.
Contact us to discuss the optimal solutions for your projects!
Protein quantification by multiplexed immunoassays
- Proximity Extension Assays (Certified service provider for Olink Proteins AB)
- Multiplexed sandwich immunoassay (Commercial kits for Luminex System)
- Automated microfluidic immunoassays (Commercial kits for ProteinSimple)
- Development of novel sandwich immunoassays (Luminex System)
Protein profiling by alternative immunoassays
- Multiplexed assessment of optimal antibody pairs (Luminex System)
- Development of tailored immunoassays (Luminex System)
- Antibody bead array assays (Luminex System)
Additional Support Capabilities:
- Study design
- Antibodies and targets selection
- Antibody validation
- Processing of affinity proteomics data
- Statistical data analysis
Each proposed project is evaluated according to the following model:
A) Initial assessment by facility:
- Technical feasibility
- Capacity requested for the project
B) Project prioritization by committee:
- Scientific potential
- Supporting preliminary data
- Significance of facility specific technique for project
- Supports facility development (competence and techniques)
• High-throughput, exploratory protein profiling of human body fluids
• Biomarker discovery and verification in large sample cohorts
• Robust protein quantification for candidate biomarkers verification
• Antibody validation and testing
• Development of novel assays
• Statistical and bioinformatic data analysis
- 50,000 antibodies from the Human Protein Atlas project, validated on protein arrays
- 2x FLEXMAP 3D, Luminex®
- LX200, Luminex®
- MAGPIX, Luminex®
- ELLA, ProteinSimple®,
- Biomark HD, Fluidigm®
Liquid handling equipment
- FLUENT, Tecan
- 2x EVO150, Tecan
- SELMA, CyBio®
Magnetic bead handling equipment
- KingFisher Flex, Thermo
- EL406 Washer Dispenser, Biotek
Examples of research projects using the facility:
- Profiling 400 plasma samples for 1100 proteins using Olink ® technology for the discovery of protein-signatures in health and disease states
- Evaluation and translation of a novel immunoassay for a cancer-related biomarker.
- Profiling 3,000 plasma samples using a customized bead array with 384 HPA antibodies for the discovery of disease-associated proteins. The aims are to identify and validate potential biomarkers; (1) to stratify populations by risk of disease progression, and (2) to monitor organ function in response to treatment.
- Design of a new immunoassay to study up to 300 proteins for their involvement in protein-protein interactions. We analyzed samples from immunoprecipitations derived from transfected human cells.
- Development of a new immunoassay to validate proposed biomarker candidates by analyzing lysates of cells collected from 200 cancer patients.
Body Fluids Profiling Publications:
• “A collaboration with clinical researchers to study plasma markers related to IBD risk”.
Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk Loci. Drobin et al., Inflamm Bowel Dis, 2018. [PMID: 30358838]
• “A service project on a longitudinal profiling of plasma from 100 newborns”
Stereotypic Immune System Development in Newborn Children, Olin et al., Cell, 2018. [PMID: 30142345]
• “Collaboration with a large biobank on plasma proteins linked with a breast cancer risk marker”. Affinity proteomic profiling of plasma for proteins associated to area-based mammographic breast density. Byström et al., Breast Cancer Res, 2018. [PMID: 29444691]
• “Screening and developing targeted plasma assays for clinical utility”.
Novel Multiomics Profiling of Human Carotid Atherosclerotic Plaques and Plasma Reveals Biliverdin Reductase B as a Marker of Intraplaque Hemorrhage Matic et al., JACC Basic Transl Sci, 2018. [ PMID: 30175270]
• “Collaboration with pharmaceutical industry to develop biomarker assays for liver injury”.
Elevated levels of circulating CDH5 and FABP1 in association with human drug‐induced liver injury. Mikus et al., Liver International, 2017. [PMID: 27224670]
• “Discovery and validation of novel plasma biomarker assays for venous thrombosis” .
PDGFB, a new candidate plasma biomarker for venous thromboembolism: results from the VEREMA affinity proteomics study. Bruzelius et al., Blood, 2016. [PMID: 27742707]
Technology Development Projects Publications:
• “Investigation of GPCR-RAMP complexes using suspension beads arrays and proximity ligation assays”.
Multiplexed analysis of the secretin-like GPCR-RAMP interactome. Lorenzen E et al., Sci Adv. 2019. [PMID: 31555726]
• “Screening antibodies to develop robust ELISA assays for biomarkers validation in plasma”.
Systematic Development of Sandwich Immunoassays for the Plasma Secretome. Häussler RS et al., Proteomics. 2019. [PMID: 31278833]
• “Application of mass spectrometry for the identification of antibody protein target in plasma”.
Systematic assessment of antibody selectivity in plasma based on a resource of enrichment profiles. Fredolini C et al., Sci Rep. 2019. [PMID: 31171813]
• “Orthogonal validation of protein profiles associated to Alzheimer's disease identified by suspension bead arrays ”.
Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer's disease. Andersson A et al., Clin Chim Acta. 2019. [PMID: 30858094]